A 33% stake in Cyclhad, a French company 
active in treatment of patients using Proton 
Therapy. The short term outlook for this entity 
remains identical as in 2021, the impairment 
on both investment and subordinated loan for 
a total of EUR 3.0 million is maintained. === Page 103 ===
IBA Annual Report 2023 
100. IBA